human biology and medicine, there are attendant issues relating to bioethics and the law (4). The collection, use, and dissemination of genetic-related data potentially invade an individual's right to privacy and raise the core issue of whether, and under what circumstances, genetic data should be released to "outside" parties such as employers and insurance companies (5). It is probably true that the variability of genetic disorders and the reality that some are more severe than others are neither fully understood nor appreciated by the general public or by employers, insurers, and various policy makers (6). In this vein, there have reportedly been instances of persons with phenylketonuria being denied health insurance (7). Other cases of "genetic discrimination" involve persons denied employment or health insurance because genetic data showed they had disorders including CharcotMarie-Tooth muscular atrophy and Friedreich's ataxia (6); asymptomatic carriers of recessively inherited diseases, including Gaucher's disease and sickle-cell anemia, have also been discriminated against (6).
There is a salient need for a wise policy pertaining to adequate protection of the privacy of genetic data. The shaping of such a policy is affected by the complex, divisive bioethical and legal roots which emanate from the collection, use, and dissemination of genetic information. Persons whose genetic profile indicates a relatively high probability of a genetic-related disorder may be disadvantaged in such realms as insurability and employment prospects. Yet, the view that persons with identifiable genetic abnormalities should not be denied insurance on the same terms as others may, rightly or wrongly, be countered by the argument that those relatively free of identifiable genetic defects should not, in effect, have to pay more for coverage (4). Insurance companies claim, moreover, that the industry would be undermined if genetic data are withheld and if those persons with genetic disorders were to aggressively seek out insurance coverage (7).
In the employment realm, knowledge gleaned from the human genome project may increasingly incite employers to exclude workers with perceived genetic risks because of concern that such workers may generate higher health care costs and become disabled prematurely (7). This type of mentality, however, would be unjust and ethically dubious in part because available genetic tests generally are poor predictors of disabling disease U).
Congress, in active cooperation with the biomedical community, should work actively toward the just regulation of genetic data and adequate protection of individual genetic privacy. Some pertinent action already has been undertaken. President Bush, in July 1990, signed the Americans With Disabilities Act (8). This new law, in general, bars employers with 15 or more employees from discriminating on the basis of disability; and medical testing is impermissible unless the testing is related to actual ability to perform the pertinent job (7). Although efforts to exclude workers based on genetic data would likely be viewed as discriminatory, the full reach of the new law, at present, is not clear. For instance, based on draft regulations developed to implement the act, it is unclear whether the act reaches those who are carriers for a recessive or X-linked disorder; additionally, the regulations allow the continued nonjob-related medical testing of prospective workers, provided the employer does not exclude such workers strictly on the basis of the test results (9). There is, plainly, a need to put more skin on the bones of the Americans With Disabilities Act.
Continued fears about malignant uses of expanded genetic knowledge flowing from the human genome project have, in fact, sparked further Congressional initiative in the form of the so-called "Human Genome Privacy Act," proposed recently by Representative Conyers (10). The proposed bill is intended broadly to safeguard the privacy of genetic information from misuse by agencies maintaining records for the purpose of research, diagnosis, treatment, or identification of genetic disorders. Members of the biomedical community, if they have not done so already, should join forces with lawmakers in tackling the thorny bioethical and legal-related issues posed by the human genome initiative and resultant genetic knowledge, including how valuable genetic data may be properly utilized without unfairly disadvantaging particular individuals in such areas as employment and insurance. LEO The article by Kennedy et al. (7) and the editorial by Henderson (2) in the Journal were read with interest. We believe it is timely to update our clinical trial (3) referenced by both authors. This information may be informative to physicians attempting to understand results of high-dose chemotherapy (HDT) and autologous bone marrow transplantation (ABMT) in breast cancer.
In his editorial, Henderson reviews Kennedy's clinical trial comparing it with ours plus three other trials (4-6) using the HDT and ABMT strategy in patients with stage IV breast cancer "responding" to conventional induction chemotherapy. He concludes that all these studies were uncontrolled and, when compared with the best standard chemotherapy regimens, they increase the complete response rate; however, duration of response and survival remains short.
We believe that we have one of the few current clinical trials with adequate accrual and follow-up to address the observation that there is a subgroup of patients with poor prognoses who achieve extended disease-free survival after HDT, which may not be expected with standard-dose chemotherapy. As an update to our 58-patient clinical trial (J), we have treated an additional 22 patients, for a total of 80 estrogenreceptor-negative (ER-) or estrogen receptor-positive (ER+) "hormonalrefractory," stage IV breast cancer patients. Our median follow-up is 83 weeks (range, 13 to 283 weeks) with median progression-free survival of 50 weeks (range, 13 to 283+ weeks). Of the 80 patients, 14 (18%) were measured progression-free from the date of initiating induction chemotherapy. One of these 14 patients died unexpectedly (the cause was secondary to unexplained hemoptysis) at 18 weeks after induction chemotherapy; she had a partial response to HDT and had been discharged from the hospital 5 weeks after HDT with full hematopoietic recovery of neutrophils and platelets. There are 13 of 14 patients alive and disease free with a minimum follow-up of 74 weeks (range, 74+ to 283+ weeks). The majority of them, 11 of 14, are progression free for more than 2 years (range, 123+ to 283+ weeks), eight of 14 are progression free for more than 3 years (range, 167+ to 283+ weeks), six of 14 are progression free for more than 4 years (range, 208+ to 283+ weeks), and three of 14 are progression free for more than 5 years (range, 275+ to 283+ weeks). Analysis of these 13 progression-free patients reveals disease at one site (nine patients) or two sites (four patients), disease predominantly distributed to visceral sites (seven of 13 patients) or regional nodes, soft tissue, or bone (six of 13 patients). Our five longest progression-free patients were not a favorably selected subgroup; they all had visceral disease distributed in lung parenchyma.
Our data are calculated on the poorprognosis groups of ER-or ER+, hormonal-refractory, stage IV breast cancer patients. On the basis of conventionaltherapy results generated by Livingston et al. (7), prolonged progression-free survival is rare in this subgroup, with a median survival of 15-18 months and at best a 5%-10% 3-year overall survival. Our progression-free survival and survival statistics are calculated after patients became "hormonal refractory" if the patients were ER+. Before starting induction chemotherapy, 35 (45%) of 80 of our patients potentially expressed resistant tumor biology because of prior treatment with cyclophosphamide-doxorubicin adjuvant or nonadjuvant chemotherapy with a median of six cycles (range, two to 18 cycles). We did not restrict entry to only young patients. (Our oldest patient was 62 years old.) We concede selection criteria were used for our trial; however, in a similar fashion, Henderson's comparative results, using "Super-CMF" (cyclophosphamide-methotrexate-fluorouracil) Adriamycin (8), used selection criteria for age and reduced renal function. His cohort reflected a minimally pretreated population of patients ineligible if they received prior treatment with more than the equivalent of two cycles of standard fluorouracil-doxorubicin-cyclophosphamide chemotherapy. "Hormonal refractoriness" is not addressed in the ER+ patients in the Henderson study (S).
Our trial included twice as many poor-prognosis (ER-) and one half as many favorable-prognosis postmenopausal patients. We included both responding patients and patients with "stable disease" in our HDT phase, which would tend to reduce the patient selection bias as compared with some other HDT clinical trials which intensify only patients who are responders. Nonlethal toxic effects include a 30% incidence of gram-positive bacterial sepsis and a 17% incidence of radiographically documented pneumonia. In an era when supportive care did not include hematopoietic growth factors, prophylactic growth factors, or prophylactic vancomycin and included patients up to age 62 years of age, the mortality rate in our trial is favorably low at 6% when compared with that in other trials using HDT followed by ABMT.
These data represent the longest reported follow-up using this tandem HDT (conditioning regimen consisting of cyclophosphamide-etoposide-cisplatin) followed by ABMT and would support this approach as being an encouraging prospect for long-term disease-free survival.
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